
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8630324/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Parkinson's Disease and Type 2 Diabetes: <scp>HbA1c</scp> Is Associated with Motor and Cognitive Severity. Movement Disorders, 2022, 37, 427-428.	3.9	6
2	Developing and assessing a new web-based tapping test for measuring distal movement in Parkinson's disease: a Distal Finger Tapping test. Scientific Reports, 2022, 12, 386.	3.3	22
3	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. Lancet Regional Health - Europe, The, 2022, 15, 100321.	5.6	13
4	The potential utility of smell testing to screen for neurodegenerative disorders. Expert Review of Molecular Diagnostics, 2022, 22, 139-148.	3.1	1
5	Surveying Global Availability of Parkinson's Disease Treatment. Journal of Parkinson's Disease, 2022, 12, 1023-1034.	2.8	2
6	Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism. Movement Disorders, 2022, 37, 478-478.	3.9	1
7	No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants. Multiple Sclerosis Journal, 2022, , 135245852210757.	3.0	2
8	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. JAMA Neurology, 2022, 79, 359.	9.0	25
9	Brain health: The hidden casualty of a humanitarian crisis. Lancet Regional Health - Europe, The, 2022, 15, 100374.	5.6	4
10	Challenges of Incorporating Digital Health Technology Outcomes in a Clinical Trial: Experiences from PD STAT. Journal of Parkinson's Disease, 2022, 12, 1605-1609.	2.8	2
11	Age-specific effects of childhood body mass index on multiple sclerosis risk. Journal of Neurology, 2022, 269, 5052-5060.	3.6	5
12	Speech-in-noise perception is a marker of preclinical Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A91.1-A91.	1.9	0
13	244†Idiopathic anosmia with motor impairment – a unique prodrome of Parkinson's?. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A83.4-A84.	1.9	0
14	026†Gene-environment interactions in multiple sclerosis: a UK Biobank study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A21.3-A22.	1.9	0
15	Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. Annals of Neurology, 2022, 92, 270-278.	5.3	10
16	Ethnic and socioeconomic determinants of dementia risk: a nested case-con- trol study in East London. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A8.2-A8.	1.9	0
17	003†Neuroanatomical signatures of genetic risk for Alzheimer's disease in healthy adults. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A101.3-A102.	1.9	0
18	Isolated REM sleep behaviour disorder: current diagnostic procedures and emerging new technologies. Journal of Neurology, 2022, 269, 4684-4695.	3.6	4

#	Article	IF	CITATIONS
19	Differences in the Presentation and Progression of Parkinson's Disease by Sex. Movement Disorders, 2021, 36, 106-117.	3.9	54
20	Genetic Risk of Alzheimer's Disease – Sleepless with the Enemy. Annals of Neurology, 2021, 89, 27-29.	5.3	0
21	The motor prodromes of parkinson's disease: from bedside observation to large-scale application. Journal of Neurology, 2021, 268, 2099-2108.	3.6	27
22	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. Annals of Neurology, 2021, 89, 803-812.	5.3	38
23	Tumor Necrosis Factor Inhibition and Parkinson Disease. Neurology, 2021, 96, e1672-e1679.	1.1	17
24	Infection and Risk of Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 31-43.	2.8	54
25	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Movement Disorders, 2021, 36, 1420-1429.	3.9	108
26	A novel capsule-based smell test fabricated via coaxial dripping. Journal of the Royal Society Interface, 2021, 18, 20210039.	3.4	1
27	No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 801-809.	2.8	3
28	Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. Npj Parkinson's Disease, 2021, 7, 33.	5.3	13
29	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
30	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. Movement Disorders, 2021, 36, 1967-1972.	3.9	3
31	Gene-Environment Interactions in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	32
32	The Influence of Socioeconomic Deprivation on Dementia Mortality, Age at Death, and Quality of Diagnosis: A Nationwide Death Records Study in England and Wales 2001–2017. Journal of Alzheimer's Disease, 2021, 81, 321-328.	2.6	19
33	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. Journal of Parkinson's Disease, 2021, 11, 1901-1915.	2.8	6
34	Domotics, Smart Homes, and Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, S55-S63.	2.8	7
35	Unhealthy Behaviours and Risk of Parkinson's Disease: A Mendelian Randomisation Study. Journal of Parkinson's Disease, 2021, 11, 1981-1993.	2.8	16
36	A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of Disease, 2021, 148, 105182.	4.4	5

#	Article	IF	CITATIONS
37	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. Npj Parkinson's Disease, 2021, 7, 87.	5.3	4
38	Mendelian Randomization—A Journey From Obscurity to Center Stage With a Few Potholes Along the Way. JAMA Neurology, 2020, 77, 7.	9.0	21
39	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
40	Big data, machine learning and artificial intelligence: a neurologist's guide. Practical Neurology, 2020, , practneurol-2020-002688.	1.1	14
41	Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. Muscle and Nerve, 2020, 62, 617-625.	2.2	19
42	Evaluating Lipid‣owering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization. Annals of Neurology, 2020, 88, 1043-1047.	5.3	11
43	The Impact of <scp>COVID</scp> â€19 on Access to Parkinson's Disease Medication. Movement Disorders, 2020, 35, 2129-2133.	3.9	40
44	Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis. Brain Communications, 2020, 2, fcaa119.	3.3	16
45	Parkinson's disease determinants, prediction and gene–environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
46	Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852096994.	3.0	0
47	Motor Dysfunction as a Prodrome of Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1067-1073.	2.8	6
48	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal <scp>Populationâ€Based</scp> Cohort. Movement Disorders, 2020, 35, 1658-1662.	3.9	11
49	BMI and low vitamin D are causal factors for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	67
50	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. Annals of Neurology, 2020, 87, 599-608.	5.3	21
51	Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review. Journal of Parkinson's Disease, 2020, 10, 31-45.	2.8	56
52	The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 775-789.	2.8	101
53	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 394-398.	1.5	11
54	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	3.9	122

#	Article	IF	CITATIONS
55	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	3.9	50
56	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
57	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. Movement Disorders Clinical Practice, 2019, 6, 462-469.	1.5	23
58	Screening performance of abbreviated versions of the UPSIT smell test. Journal of Neurology, 2019, 266, 1897-1906.	3.6	37
59	The Parkinson's phenome—traits associated with Parkinson's disease in a broadly phenotyped cohort. Npj Parkinson's Disease, 2019, 5, 4.	5.3	34
60	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and αâ€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
61	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
62	Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations. Movement Disorders, 2019, 34, 480-486.	3.9	69
63	The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. Journal of Neurology, 2018, 265, 285-290.	3.6	13
64	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€perceptual deficits. Movement Disorders, 2018, 33, 544-553.	3.9	25
65	No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. Journal of Neurology, 2018, 265, 1089-1095.	3.6	67
66	Dopamine reuptake transporter–singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
67	Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. Practical Neurology, 2018, 18, 166-169.	1.1	6
68	Laughter isn't always the best medicine. BMJ: British Medical Journal, 2018, 363, k4579.	2.3	6
69	Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease. Annals of Neurology, 2018, 84, 191-199.	5.3	43
70	Association between diabetes and subsequent Parkinson disease. Neurology, 2018, 91, e139-e142.	1.1	171
71	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	3.9	59
72	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34

#	Article	IF	CITATIONS
73	Subtle motor disturbances in PREDICT-PD participants. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 212-217.	1.9	19
74	Viral hepatitis and Parkinson disease. Neurology, 2017, 88, 1630-1633.	1.1	47
75	Observations on a 2-Step Approach to Screening for Parkinson Disease. JAMA Neurology, 2017, 74, 1506.	9.0	1
76	Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview. Advances in Neurobiology, 2017, 15, 55-92.	1.8	2
77	Nonsyndromic Parkinson disease in a family with autosomal dominant optic atrophy due to <i>OPA1</i> mutations. Neurology: Genetics, 2017, 3, e188.	1.9	27
78	Technologies Assessing Limb Bradykinesia in Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 65-77.	2.8	50
79	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Medicine, 2017, 14, e1002314.	8.4	152
80	Challenges of modifying disease progression in prediagnostic Parkinson's disease. Lancet Neurology, The, 2016, 15, 637-648.	10.2	78
81	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
82	<scp>M</scp> endelian <scp>R</scp> andomization — the <scp>K</scp> ey to <scp>U</scp> nderstanding <scp>A</scp> spects of <scp>P</scp> arkinson's <scp>D</scp> isease <scp>C</scp> ausation?. Movement Disorders, 2016, 31, 478-483.	3.9	23
83	Constipation preceding Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 710-716.	1.9	152
84	Webâ€based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	3.9	6
85	Systematic review and metaâ€analysis of salivary protein concentration in <scp>P</scp> arkinson's disease. Movement Disorders, 2015, 30, 1971-1972.	3.9	2
86	Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurology, The, 2015, 14, 57-64.	10.2	487
87	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	10.2	179
88	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as aÂpotential marker of disease severity. Parkinsonism and Related Disorders, 2015, 21, 1251-1255.	2.2	41
89	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. PLoS ONE, 2014, 9, e96260.	2.5	52
90	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	1.9	90

#	Article	IF	CITATIONS
91	Bone health in Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1159-1166.	1.9	114
92	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
93	Rapid-onset flaccid paraplegia caused by multiple myeloma dumbbell tumour. Practical Neurology, 2014, 14, 268-269.	1.1	Ο
94	Metaâ€analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
95	Severe dysphagia as a presentation of Parkinson's disease. Movement Disorders, 2012, 27, 457-458.	3.9	24
96	Teaching Neuro <i>Images</i> : Microhemorrhages resulting from cranial radiotherapy in childhood. Neurology, 2010, 75, e2-3.	1.1	2
97	Mild parkinsonian signs: the interface between aging and Parkinson's disease. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, 20, .	0.1	1